Nettoomsättningen inkom något lägre än vad vi estimerat för Q4’22.
Transfer Group publicerade den 22 februari 2023 bolagets delårsrapport för fjärde kvartalet år 2022.
I dag offentliggjorde Risk Intelligence sin delårsrapport för det fjärde kvartalet 2022.
NOSIUM har idag publicerat bolagets delårsrapport för fjärde kvartalet 2022.
Sales -3% and adj. EBITA -8% vs. ABGSC SolidEngineer and earn-out revaluations affect reported resul...
Redeye comments on Isofol Medical’s Q4 2022 report after shareholders voted against the board’s prop...
Redeye comments on Scandion Oncology’s Q4 2022 report, with a new CEO in place and two study readout...
Eurocons rapport för fjärde kvartalet kom in starkare än vi förväntat oss på alla punkter.
Redeye is positively surprised by I-Tech’s very strong end of 2022, posting organic sales growth of ...
Sales SEK 721m -13% vs. ABGSCe 824m Adj. EBITDA SEK 13.
Higher sales, but also higher losses Solid demand outlook, some caution on margins Margins and neg.
Sales -7% vs ABGSCe, adj. EBITA -7% vs ABGSCe Outlook uncertain, '23e-'24e adj.
Scanfil’s year concluded on a strong note without any big surprises.
Redeye comments on Zordix Q4-report which saw revenue in line with expectations while EBITDA came in...
Atria reported Q4 adjusted EBIT of EUR 16.7m, 39% above our estimate (no quality consensus available...
Raketech just released a solid Q4 report, and a better than expected start to the first quarter.
Redeye saw sales lower than our expectations in the Q4 report partly due to the delays for Carbonhan...
Q4 results Arise delivered sales of SEK 106m, which was 10% below our expectations of SEK 118m.
Redeye notes that Egetis’ Q4 report presented SEK5.
Redeye is encouraged by the news that Zwipe starts the first proof-of-concept together with Civix fo...
